Abstract
Human cytidine deaminase (CDA) is an enzyme prominent for its role in catalyzing metabolic processing of nucleoside-type anticancer and antiviral agents. It is thus a promising target for the development of small molecule therapeutic adjuvants. We report the first crystal structure of human CDA as a complex with a tight-binding inhibitor, diazepinone riboside 1. The structure reveals that inhibitor 1 is able to establish a canonical π/π-interaction with a key active site residue, Phe 137.
| Original language | English |
|---|---|
| Pages (from-to) | 658-660 |
| Number of pages | 3 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 48 |
| Issue number | 3 |
| DOIs | |
| State | Published - 10 Feb 2005 |
| Externally published | Yes |